Skip to main content

Table 1 Baseline characteristics of all the patients (n = 498)

From: Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy

Factor All patients (%) prophylaxis of TMP/SMX p
Yes No
Age >  60 years 182 (36.5%) 112 (61.5%) 70 (38.5%) 0.774
≤ 60 years 316 (63.5%) 199 (63%) 117 (37%)  
Gender Female 234 (47%) 158 (67.5%) 76 (32.5%) 0.033
Male 264 (53%) 153 (58%) 111 (42%)  
ECOG PS > 1 57 (11.4%) 42 (73.7%) 15 (26.3%) 0.08
PS ≤1 441 (88.6%) 269 (61%) 172 (39%)  
Elevated LDH YES 231 (46.4%) 145 (62.8%) 86 (37.2%) 0.926
NO 267 (53.6%) 166 (62.2%) 101 (37.8%)  
Smoking history YES 131 (26.3%) 77 (58.8%) 54 (41.2%) 0.344
NO 367 (73.7%) 234 (63.8%) 133 (36.2%)  
Ann Arbor stage I 88 (17.7%) 45 (51.1%) 43 (48.9%) 0.071
II 162 (32.5%) 103 (63.6%) 59 (36.4%)  
III 97 (19.5%) 60 (61.9%) 37 (38.1%)  
IV 151 (30.3%) 103 (68.2%) 48 (31.8%)  
BM involvement YES 27 (5.4%) 19 (70.4%) 8 (29.6%) 0.422
NO 471 (94.6%) 292 (62%) 179 (38%)  
IPI risk (score) Low (0–1) 236 (47.4%) 140 (59.3%) 96 (40.7%) 0.378
Low–intermediate-2 126 (25.3%) 81 (64.3%) 45 (35.7%)  
High–intermediate-3 80 (16.1%) 50 (62.5%) 30 (37.5%)  
High (4–5) 56 (11.2%) 40 (71.4%) 16 (28.6%)